Unraveling the Role of Angiogenesis in Cancer Ecosystems

Iratxe Zuazo-Gaztelu and Oriol Casanovas*

Tumor Angiogenesis Group, ProCURE, Catalan Institute of Oncology – IDIBELL, Barcelona, Spain

Activation of the tumor and stromal cell-driven angiogenic program is one of the first requirements in the tumor ecosystem for growth and dissemination. The understanding of the dynamic angiogenic tumor ecosystem has rapidly evolved over the last decades. Beginning with the canonical sprouting angiogenesis, followed by vasculogenesis and intussusception, and finishing with vasculogenic mimicry, the need for different neovascularization mechanisms is further explored. In addition, an overview of the orchestration of angiogenesis within the tumor ecosystem cellular and molecular components is provided. Clinical evidence has demonstrated the effectiveness of traditional vessel-directed antiangiogenics, stressing on the important role of angiogenesis in tumor establishment, dissemination, and growth. Particular focus is placed on the interaction between tumor cells and their surrounding ecosystem, which is now regarded as a promising target for the development of new antiangiogenics.

Keywords: angiogenesis, angiogenic tumor ecosystem, sprouting angiogenesis, vasculogenesis, vasculogenic mimicry, intussusception, antiangiogenics

FOUNDATIONS OF THE TUMOR STROMAL ECOSYSTEM

The simplistic view of a tumor as a conundrum of just mutant cells engaged in clonal expansion is currently evolving into a more holistic approach where tumors are regarded as organ-like structures (1, 2). Genetic deletion, overexpression, mutation, and translocation events certainly lead to the transformation of a normal cell into a malignant cell which will then undergo sustained proliferation. However, for neoplastic cell expansion and growth, the ability to handle the surrounding stroma to create a favorable ecosystem becomes imperative (3). Hence, the information enclosed in the rich and ever-changing tumor microenvironment is crucial for the understanding of antitumor drug sensitivity.

The tumor microenvironment is formed by a tangled combination of both tumor and stromal cells, extracellular matrix (ECM), and secreted factors, thus perfectly fitting in the definition of an ecosystem (4, 5). Alteration of the gene expression of tumor cells provokes a disruption in the normal tissue homeostasis, favoring the secretion of certain molecules (cytokines, growth factors, etc.) that recruit stromal cells. Cells composing the tumor stroma are cancer-associated fibroblasts (CAFs), endothelial cells, pericytes, adipocytes, and immune cells, including monocytes, macrophages, lymphocytes, and dendritic cells (DCs), among others (Figure 1). These cells are enclosed in heterogeneously deposited ECMs and are affected by changing biophysical parameters including oxygenation and pH (6–9).

The insight into the dynamic action of the tumor ecosystem has improved exponentially over the last years, regarding the stroma as an integral part of tumor initiation, progression, and malignization. Stromal elements hold the key for prognostic and response predictive information. As such, therapeutic targeting of stroma-related processes are continually described. Tumor cells
dwell in symbiosis with the rest of the body, mimicking and coopting several normal physiological processes on behalf of their surrounding stroma. Together with sustained proliferation and recruitment of immune cells, angiogenesis is one of the acknowledged promoters of tumor growth and survival (6, 10). In fact, tumor-associated vessels also contribute to dissemination of tumor cells by abetting their entry into the circulatory system and aiding in the generation of the pre-metastatic niche. In this review, we will further explore the role of angiogenesis as a key modulator inside the tumor ecosystem. To do so, we will first describe the different mechanisms responsible for tumor angiogenesis and we will focus later on the action of antiangiogenic drugs upon the stroma.

**INSIGHT INTO THE ANGIOGENIC TUMOR ECOSYSTEM**

To grow beyond a limited size, all solid tissues require a proper vasculature that grants oxygen, nutrients, and waste disposal. Since neoplasms are no exception to this rule, early activation of angiogenic processes is mandatory to sustain the deregulated proliferation of tumor cells. Apart from serving as nutrient, oxygen, and waste transport providers, vessels also facilitate dissemination of tumor cells to distant sites, promoting metastasis. Tumor angiogenesis is thus defined as the process of blood vessel creation, penetration, and growth in the tumor ecosystem.

The angiogenic program is switched on in response to hypoxia, which, together with the lack of nutrients, bolsters the expression of inflammatory signals and cytokines that recruit vascular cells for the tumor vessel plexus formation (11, 12). Early during tumor progression, hypoxia triggers the transcription of several genes that are key mediators of the angiogenic process, such as VEGF and PDGF (13). Mechanistically, activation of the angiogenic process involves the breakdown of the vascular ECM at different levels for subsequent endothelial cell invasion and tube formation (14). Apart from the role of tumor cells as principal secretors of endothelial cell promoters, the interplay with other stromal cells such as pericytes is also needed for neovessel stability.

For studying tumor angiogenesis, different approaches exist. A compilation of the currently used in vivo, ex vivo, and in vitro bioassays has been recently published as a collaborative work of some of the main experts in the angiogenesis field (15). Briefly, in vivo experimental models allow the study of mechanisms, kinetics, and dynamics in the context of a complex organism. The chorioallantoic membrane of a chicken embryo is used without
Mechanisms Involved in Tumor Vessel Generation

Nearly 40 years after the studies that laid the foundations in the field (21), research in tumor angiogenesis has extensively matured, permitting the gathering of detailed knowledge over the processes that govern pathological vessel proliferation. Vessels are ordered tubular networks that permit transportation of nutrients, cells, and gases. Apart from providing nutrients, vessels function as carriers of instructive trophic signals needed for organ morphogenesis (22). Different types of vessels, including arteries, veins, and capillaries, are formed by a luminal side surrounded by a monolayer of endothelial cells. On the outside, following the basement membrane, vessels are covered by a layer of mural accessory cells composed of pericytes and vascular smooth muscle cells.

Archetypal mechanisms for neovascularization include vasculogenesis and sprouting angiogenesis (Figures 2A,B). Critical for the formation and remodeling of vessels during development, both mechanisms are reactivated during tumor progression. Vasculogenesis is defined as the de novo formation of blood vessels as a consequence of vascular progenitor cell differentiation, whereas sprouting angiogenesis stands for the formation of new vascular structures from a preexisting vessel network. Recently, the role of other less frequent vascular formation mechanisms during tumor growth has been described, including vasculogenic mimicry (VM) and intussusception (Figures 2C,D). Usually, neither of the mechanisms are mutually exclusive and even seem to act simultaneously in pathological neovascularization.

Sprouting Angiogenesis

By far, sprouting angiogenesis is the best known angiogenesis-promoting mechanism used by tumor cells to induce their own vascularization from preexisting host capillaries (Figure 2A). A thorough interplay between ECM components, cells, and soluble factors is required for this process.

**Figure 2** | Mechanisms implicated in blood vessel formation. In the tumor ecosystem, blood vessels grow by sprouting angiogenesis (A). In addition, less frequent neovascularization mechanisms include recruitment of bone marrow-derived endothelial progenitor cells (EPCs) (B), intussusceptive microvascular growth (C), and vasculogenic mimicry (D). Figure was created using Servier Medical Art according to a Creative Commons Attribution 3.0 Unported License guidelines 3.0 (https://creativecommons.org/licenses/by/3.0/). Simplification and color changes were made to the original cartoons.
Vasculogenesis

The term “vasculogenesis” was conceived by Werner Risau, to define the physiological formation of the vascular plexus from the mesoderm as a consequence of angioblast differentiation (32). During tumor vasculogenesis, endothelial progenitor cells (EPCs) are mobilized and recruited in response to several chemokines, cytokines, and growth factors produced by tumor and stromal cells (Figure 2B). In particular, tumor cells produce a plethora of cytokines and proangiogenic factors, such as VEGF, that recruit bone marrow-derived DCs and induce their proliferation and differentiation (33). In hypoxic conditions, HIF is able to activate the transcription of VEGF, PDGF, stromal-derived factor 1 (SDF-1), and C-X-C chemokine receptor type 4 (CXCR4) (34). Studies with loss of function of HIF demonstrated an inhibition of EPC proliferation and differentiation. The contribution of vasculogenesis to tumor progression has also been demonstrated by knockout studies where some initiator molecules, such as inhibitors of differentiation factors, were genetically ablated. This approach provoked a disruption of tumor vascularization, angiogenesis blockade, and tumor growth impairment that was rescued by the restoration of the mobilization factors after bone marrow transplantation (35).

The first step of EPCs mobilization starts with the proangiogenic factor-mediated activation of the matrix metalloprotease 9 (MMP9) in the osteoblastic zone. Activated MMP9 proteolytically processes the membrane bound Kit ligand to its active soluble conformation. Kit is a stem cell-active migratory cytokine that induces migration and release of EPCs into the circulatory system (36). Once homed, EPCs are either incorporated into angiogenic sprouts or into the endothelial cell monolayer, aided by selectins and integrins (37). Endothelial cell maturation is substantially mediated by VEGF, which also contributes to vessel size establishment. Besides, EPCs share a paracrine mechanism that also triggers tumor angiogenesis by the release of proangiogenic molecules at the sites of neovascularization (38).

Depending on the experimental cancer model and the type of the tumor, vasculogenesis contributes to tumor vessel formation processes ranging from 0.1 to 50% of all vessels. As an example, the tumor ecosystem of hematopoietic and lymphoid tissues is more dependent on EPCs. Besides its role in primary tumor growth, vasculogenesis is also involved in dissemination and metastasis. SDF-1 produced by immune cells might attract EPCs to distant sites and once there spontaneously induce SDF-1 production, generating a gradient of this molecule that will serve as a chemoattractant of tumor cells. The interaction between SDF-1, secreted by EPCs, and its CXCR4 receptor, mainly expressed by tumor cells, would promote extravasation and development of the pre-metastatic niche (39). Moreover, the activation of MMP9 by EPCs is also related to an increase in tumor cell migration and invasion, confirming the role of vasculogenesis in metastatic niche formation (40).

Vasculogenic Mimicry

Vasculogenic mimicry refers to the ability of some malignant cells to start the dedifferentiation process to adopt multiple cellular phenotypes, including endothelial-like properties (41).
(Figure 2C). Those cells finally converge in de novo vasculogenic-like networks composed of red blood cells that are able to contribute to circulation (42). In this way, cells undergoing VM are able to reproduce the pattern of an early embryonic vascular plexus, providing the tumor ecosystem with an additional circulatory system independent of angiogenesis.

The process of VM was observed in highly invasive melanoma cells, whose phenotype reverted to an embryonic-like state and increased cell plasticity, including expression of endothelium-associated genes such as Ephrin-A2 and VE-cadherin (43). Release of ECM components, hypoxia, and activation of transmembrane metalloproteinases has been described as VM promoters (44). Although the occurrence of VM is relatively infrequent within tumors, it has been related to aggressive tumors, an increased risk of metastasis and poor prognosis (45).

**Intussusception**

Vessel intussusception or intussusceptive microvascular growth (IMG) is defined as a developmental intravascular growth mechanism consisting of the splitting of preexisting vessels into two new vascular structures. This was first described in postnatal remodeling of lung capillaries (46) (Figure 2D). During intussusception, endothelial cell proliferation is not required, which ultimately makes it a rapid process that occurs within hours or minutes if compared with sprouting angiogenesis. Further, IMG does not rely on endothelial cell proliferation, but it is rather a remodeling process of the endothelial cells that happens as a consequence of both their narrowing and volume increase. IMG is described to occur after sprouting angiogenesis or vasculogenesis, as a mean of expanding the capillary plexus without the need of a high-metabolic demand (47).

The “touching spot” between endothelial cells from opposite walls initiates the IMG process. To reinforce the transendothelial cell bridge, the endothelial bilayer is formed with cell–cell junctions and the interstitial pillar is formed. Pericytes and other mural cells are recruited to cover the interstitial wall, which is later widened, allowing endothelial cell retraction and the creation of two independent vessels (47). By using this mechanism, a large vessel is able to split into many smaller functional vessels. Although the precise mechanism underlying IMG is not fully described, alterations in blood flow dynamics, wall stress over pericytes, changes in shear stress on endothelial cells sensed by absence of CD31 and VEGF are some of the possible events that result in IMG initiation (48).

Intussusceptive microvascular growth has been reported in mammary, colorectal, and melanoma tumors (49). In human melanomas, a correlation between VEGF and intussusceptive angiogenesis was found, together with a higher number of intraluminal tissue folds (50). This scenario suggests that spraying angiogenesis inhibition could stimulate IMG. Taking into account that intussusceptive angiogenesis only occurs in preexisting vascular structures, its most important contribution to tumor malignization is its ability to augment the number and complexity of tumor microvessel networks already created by other angiogenic mechanisms. Ultimately, the creation of new vessel structures also provides additional surface for further activation of spraying angiogenesis.

**ROLE OF TUMOR ECOSYSTEM IN PROMOTING ANGIOGENESIS**

Inside the tumor ecosystem, tumor cells are the main producers of the proangiogenic molecules that switch on the angiogenic program. Among the molecules that regulate this process, PDGF, HGF, FGF, and, particularly, VEGF and its cognate receptors (VEGFRs) are the driving force, owing to their specific expression on tumor and endothelial cells. Nevertheless, other cells composing the tumor ecosystem also contribute to tumor angiogenesis and their role must be considered throughout an integrative approach (Figure 1).

**Cancer-Associated Fibroblasts**

Cancer-associated fibroblasts normally originate from tumor or resident stroma, even though they can also differentiate from bone marrow precursors. While CAF-mediated secretion of proteases contributes to ECM degradation, CAFs also produce and deposit ECM, remarking a dual role for these cells in ECM remodeling. Besides, CAFs also secrete multiple angiogenic cues, participating in tumor growth and progression (51). Due to their primary localization at the leading edge of the tumor, where expanded vessel supply is demanded, the contribution to angiogenesis by stromal fibroblasts becomes crucial (52, 53).

One of the most important molecules secreted by stromal CAFs is VEGF-A, which was found to be induced in the stroma of both spontaneously arising and implanted tumors of genetically engineered mice with a reporter for VEGF-A (54). Actually, in ovarian carcinomas, most angiogenic growth factors are provided by CAFs rather than by malignant cells (55). CAFs also supply other factors such as angiopoietin-1 and -2, which are needed for neovascular stabilization (56).

**Immune Cells**

The tumor ecosystem constitutes a crucible of heterogeneous immune cell populations, resulting in tangled interactions between tumor cells and stroma. Immune cells have a remarkable role during the regulation of different aspects of tumor growth, such as modulation of angiogenesis and immune system evasion (57). Particularly, the contribution of macrophages, DCs, and mast cells is further explored in this section.

Tumor-associated macrophages (TAMs) represent one of the most abundant leukocyte population in the tumor ecosystem and their presence correlates with a reduction in survival in most tumor types (58). Regarding their phenotype, macrophages can be classified into the classically activated M1 and alternative activated M2 subsets. Whereas M2 macrophages show a proangiogenic phenotype, M1 macrophages have been described as antitumor effectors (59). TAMs often shift toward the M2 phenotype, becoming an important supplier of angiogenic cytokines and ECM remodeling molecules (60–62). Indeed, in different types of tumors, macrophage presence has been correlated with high vascularity (63, 64). Apart from the canonical signaling pathways, alternative proangiogenic molecules such as semaphorins and plexins have been also described as mediators of the macrophage–endothelial cell cross talk (65).
Dendritic cells, due to their potent antigen-presenting ability, are considered a critical factor in antitumor immunity (66). Nevertheless, defective myelopoiesis inside the tumor ecosystem renders DCs incompetent (67). A role for DCs in tumor angiogenesis has been described after the finding that immature DCs increased neovascularization in implanted tumor models, while depletion of DCs revoked angiogenesis (68).

Mast cells were found more than 30 years ago to be accumulated in tumors before the onset of angiogenesis, residing in close proximity to blood vessels (69). Those granulocytes participate in tumor rejection by IL1, IL4, IL6, and TNF-α production. However, mast cells also promote tumor growth by increasing the angiogenic supply, degradation of the ECM and immunosuppression (70). In detail, mast cells release angiogenic cytokines, such as VEGF, FGF-2, and TGF-β, among others (71).

**Vascular-Associated Components**

Even though endothelial cells are the main players of the angiogenic tumor ecosystem, other components of the vascular system, such as platelets and pericytes, are also necessary for the proangiogenic switch. For instance, platelets, best known for their role in assisting the blood clotting process, have also been described as proangiogenic cells. Upon interaction with tumor cells, platelets are able to release VEGF from α granules (72, 73).

The contractile cells that surround the basement membrane of vessels are known as pericytes. In absence of angiogenesis, pericytes commonly express proteins such as PDGFRβ, NG2, and desmin and lack expression of α-SMA. Upon the activation of angiogenic signaling via PDGF, TGF-β, angiopoietin, and Notch, tumor pericytes loosen their attachment to the vessel, leading to a higher permeability of blood vessels (74, 75). Particularly, the recruitment of pericytes to the tumors highly depends on PDGF-B ligand production by endothelial cells (76, 77).

Nevertheless, the ultimate outcome of pericyte-derived signaling remains to be fully elucidated, since it seems to be context dependent. On the one hand, ectopic expression of PDGF-B in a mouse melanoma model increased tumor growth, indicating that a more stable and functional neovascularization was achieved through pericytes (78, 79). On the other hand, PDGF-B transfection into colorectal and pancreatic tumor cell lines inhibited tumor growth as a consequence of the angiostatic effect of recruited pericytes (80). Pericytes are also involved in the control of the metastatic spread of tumor cells (81). In fact, an increased rate of metastasis was described in a pancreatic neuroendocrine tumor mouse model genetically designed to be pericyte-poor. It remains to be elucidated whether their protective effect against metastasis is due to their active participation or as a consequence of their passive role as a physical barrier to extravasation.

**ECM and the Vascular ECM**

The organization and composition of the matrix that supports the cells of the tumor ecosystem is essential for the regulation of angiogenesis. In fact, mice bearing alterations in ECM molecules such as collagen, laminin, and fibronectin exhibit vascular abnormalities (82). Vessel ECM is constituted by the basement membrane BM, which is mainly composed of collagen IV and laminin (83) and provides a broad binding surface for other ECM proteins, integrin receptors, and growth factors. Those interactions lead to the activation of many signaling pathways, such as PI3K, AKT, and MAPK, which are involved in adhesion, migration, invasion, and proliferation, thus contributing to tumor angiogenesis (84).

The interstitial matrix that surrounds the BM, which comprises collagen I, II, and III, as well as fibronectin and fibrinogen, also contributes to tumor angiogenesis. It primarily functions as a reservoir of regulatory molecules, such as angiogenic growth factors, cytokines, and proteolytic enzymes (85). Moreover, binding of VEGF to fibronectin has been found to enhance the activity of VEGF Concomitantly, tumor and stromal cells produce proteolytic enzymes, such as MMPs, that release fragments with promigratory and proangiogenic properties (86), besides the activation of ECM-sequestered growth factors (87).

**THE ANGIOGENIC SWITCH IN TUMORIGENESIS**

In the absence of new vasculature, during the avascular phase, tumor growth is normally limited to no more than 1–2 mm³. Tumors obtain nutrients and oxygen from nearby blood vessels and angiogenic processes are not observed. The avascular tumors reach a stable state characterized by a balance between proliferation and apoptosis. To grow beyond the restricted size and sustain unlimited proliferation, tumors require their vascular network to be extended. This transition from this avascular state to the angiogenic phase is commonly known as “angiogenic switch” and occurs early during tumor progression (88). In pursuance of angiogenic activation, tumor cells need to undergo numerous genetic and epigenetic rearrangements that grant them the angiogenic potential for both tumor growth and latter metastasis. Indeed, a plethora of experiments have shown that the lack of a functional vascular network leads to tumor apoptosis or necrosis, reinforcing the importance of tumor vasculature for tumor thriving (89).

The angiogenic switch depends on a dynamic balance between positive (proangiogenic) and negative (antiangiogenic) factors controlling vascular homeostasis (90). Under physiological conditions, this balance is shifted toward negative regulation of angiogenic processes, thus maintaining the quiescence of the vasculature. Once tumor progression is started, different mechanisms, such as the loss of tumor suppressor genes and oncogene upregulation, revert this balance. During the first steps of tumorigenesis, high levels of strong angiogenic inducers, such as VEGF and FGF, are released to the tumor ecosystem. VEGF is regarded as the canonical angiogenesis initiator and has been found to be expressed in most types of cancer in response to different stimuli. Besides hypoxia, hypoglycemia, and growth factors, overexpression of the oncogene Myc produces a 10-fold increase in VEGF levels (91). Apart from VEGF, other proangiogenic molecules upregulated for the engagement of tumor angiogenesis are PDGF, EGF, TGF-β, FGF, MMPs, and angiopoietins.

Aiming at evading the ECM-associated endogenous inhibitors, tumor cells are able to further upregulate proangiogenic factors and even lose the expression of tumor suppressor genes such as p53 (92, 93). Moreover, tumor cell metabolism shifts
and becomes highly acidic, as a consequence of the Warburg effect (94). The net increase in glucose consumption produces an abnormal lactic acid release that turns lowers extracellular pH (95). High levels of lactate have been correlated with EMT, dissemination, and metastases of several types of human cancer, such as melanoma and Lewis lung carcinoma (96–98). In detail, acidification further promotes angiogenesis through the increased expression of VEGF (99).

**The Hypoxic Tumor Ecosystem**

Lack of oxygen inside the tumor occurs as an inevitable consequence of the rapid expansion of the tumor mass. Neoplasms have been generally described as highly hypoxic structures, bearing distorted, and abnormal vascular networks, inefficient in oxygen transportation (100). Hypoxia is known to upregulate proangiogenic inducers and endothelial–pericyte destabilizing molecules (Ang-2) and downregulate inhibitors. Furthermore, mobilization of bone marrow–derived precursor cells and recruitment of immune cells to the tumor ecosystem is also positively controlled by hypoxia (101). By changing the cytokine milieu, hypoxia can also induce an immunosuppressive microenvironment, allowing immune system evasion by cancer cells (102).

Hypoxia also produces a metabolic switch to apoptosis inhibition, anaerobic metabolism, increased invasiveness, EMT, and metastasis (103). A stem-like phenotype is induced concomitantly with the release of cytokines like IL-6. Consistently, hypoxia-driven expression of VEGF, MMPs, and ANGPTL4 is crucial for intravasation (104). In detail, ANGPTL4 expression disrupts vascular endothelial tight junctions and augments permeability, thereby altering transendothelial barriers (105).

**CONTRIBUTION OF ANGIOGENESIS TO METASTASIS AND INVASION**

Aside from the role in primary tumor ecosystem maintenance, tumor angiogenesis enables tumor cell invasion and dissemination and favors the creation of new secondary tumor ecosystems at metastasized sites. VEGF-mediated stimulation of blood and lymphatic endothelial cells provides a wide vascular area for intravasation of tumor cells, apart from increasing vascular permeability. In tumor endothelial cells, VEGF upregulates protease secretion, contributing to basement membrane degradation, and increasing the expression of molecules that mediate in tumor–endothelial cell interactions (106).

Other stromal cells also participate in the angiogenic-driven metastasis process. Pericytes covering tumor vessels are more loosely attached to endothelial cells, affecting endothelial cell survival, and increasing the number of intercellular gaps that permit easy access for tumor cell intravasation (81, 107). As a consequence of the increased vascular leakiness, passive escape of tumor cells is highly induced (108).

**BLOCKING VESSELS IN THE ECOSYSTEM**

Fighting neovascularization to halt tumor progression has become a critical step of the long-established theory of angiogenic activation for tumor growth. In fact, more than 40 years have passed since tumor angiogenesis inhibition was first introduced as a potential therapeutic strategy (21, 109). Since then, many drugs targeting tumor vascularization have proven successful in the treatment of different tumors. Such is the case for the first FDA-approved angiogenesis inhibitors sunitinib (Sutent®) and bevacizumab (Avastin®), which demonstrated promising results in the treatment of kidney and colorectal cancers (110, 111).

Currently, using standard chemotherapy alone for cancer treatment has proven inefficient due to low selectivity of tumor cells, producing toxicity in normal tissues with high-proliferation rates (e.g., bone marrow, hair follicles, and gastrointestinal tract). Besides, tumor cells become resistant, whereas the abnormality of tumor vasculature impairs efficient drug delivery (112). On the contrary, with thousands of people being treated with VEGF inhibitors around the world, antiangiogenic targeting surely serves as an example of specific tumor ecosystem disruption for efficient cancer treatment.

There are different reasons underlying the success of tumor vascular targeting, involving both tumor and stromal cell interplay. First, the concept that tumors are dependent on multiple factors extrinsic to themselves, so rendering them without a functional vasculature that delivers oxygen and nutrients should kill them. Second, stromal cells, unlike neoplastic cells, are genetically more stable, being less likely to develop resistance to therapy. This makes angiogenesis a really attractive target for drug development. Third, tumors have always been described as highly vascular structures, meaning that anti-vascular targeting could be aimed at the treatment of a wide range of solid tumors (113, 114).

Taking into account the abundance of mechanisms involved in tumor angiogenesis, blood vessel formation processes can be inhibited at many different levels (Figure 3). Actually, distinct types of compounds, such as antibodies and small molecules, have been developed as antiangiogenic drugs. Production of antibodies presents some disadvantages for the pharma companies regarding the expensive requirement of mammalian cell production systems, dependence on disulfide bonds for stability, overcoming the tendency to aggregation, and low expression yields. Consequently, other promising molecules such as small globular proteins, aptamers, and peptides are currently being investigated (115). Noteworthy, not all antiangiogenic compounds have the same cellular effects nor the same therapeutic relevance. The main effects of angiogenic inhibitors can be classified according to their effects on: inhibition, regression, or normalization of tumor blood vessels. In this section, some of the main mechanisms to inhibit vascular malignization will be highlighted.

**Direct Vessel Signaling Inhibition**

Endothelial cell activation is commonly initiated upon stimulation of tyrosine kinase (TK) receptors by growth factors. As previously stated, VEGF is the most important growth factor involved in tumor angiogenesis, and its inhibition influences endothelial cell survival, growth, migration, blood flow, and stromal cell recruitment (116, 117). Some of the VEGF-inhibiting approaches imply neutralization of the ligand or the receptor by specific antibodies, soluble receptors, small-molecule inhibitors
FigURe 3 | Tumor angiogenesis inhibition strategies. Due to the complexity of tumor angiogenesis, it can be inhibited at different levels. Direct vessel signaling inhibition approaches include VEGF ligand inhibitors, VEGFR receptor inhibitors, and other growth factors inhibitors released by stromal or tumor cells. Other examples are tyrosine kinase (TK) inhibitors, that block endothelial and pericyte cell activation, thus blocking their proliferation, migration, and survival. Novel antiangiogenic strategies are directed toward endothelial progenitor cell (EPC) recruitment inhibition, via stromal-derived factor 1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) signaling blockade, and extracellular matrix (ECM) remodeling inhibition. Figure was created using Servier Medical Art according to a Creative Commons Attribution 3.0 Unported License guidelines 3.0 (https://creativecommons.org/licenses/by/3.0/). Simplification and color changes were made to the original cartoons.

of TK phosphorylation, and the direct inhibition of its intracellular signaling pathway (Figure 3). Thus far, 10 molecules that target VEGF or VEGFR have been approved for the treatment of various malignancies (118).

Since TK receptors are expressed both in tumor and vascular cells, TK inhibitors (TKIs) are regarded as a useful drugging strategy for their potentially dual effect (Figure 3). They are capable of blocking tumor cell proliferation and proangiogenic signaling simultaneously (119). However, the efficacy of TKIs varies depending on the different expression levels of the targeted ligands and effectors depending on the tumor type. Some strategies include compounds that block the binding site of the ATP in the TK receptor, causing the blockade of the receptor. Other TKIs aim at preventing the binding of the TK ligand with antibodies that block the growth factor or the binding site of the receptor (120).

The best known TKIs that block VEGFR and PDGF signaling are sorafenib, sunitinib, and pazopanib. Sorafenib is a synthetic compound that inhibits both Raf signaling, involved in cell division and proliferation, and VEGFR-2 and PDGFRβ signaling, modulators of angiogenesis (121). Its use is approved in the treatment of hepatocellular, thyroid, and renal cell carcinomas. Similarly, sunitinib is a TKI that, apart from blocking VEGFR-2 and PDGFRβ, is able to inhibit c-kit. The FDA approved the use of sunitinib for the treatment of imatinib-resistant gastrointestinal stromal tumor and renal cell carcinoma (122).

Recently, anti-VEGFR2 antibody ramucirumab has received the FDA approval for second-line gastric cancer treatment (123). Another example includes pazopanib, a VEGFR-1, -2, -3, c-kit, and PDGFR inhibitor, approved for renal cell carcinoma and soft tissue sarcoma (124).

Novel Antiangiogenic Approaches
Vascular Ecosystem Inhibition

Considering the contribution of EPCs to tumor angiogenesis and metastasis, blocking of EPC recruitment is a recently explored strategy for new blood vessel and metastatic niche abrogation (125) (Figure 3). To achieve so, specific targeting of molecules involved in EPC homing and recruitment from the bone marrow is an interesting approach. SDF-1/CXCR4 signaling axis is the main regulator of EPC mobilization and, as such, antagonists and antibodies against CXCR4 have been proposed (126). The action of these compounds is based on their ability to prevent the chemokine gradient that permits the homing of EPCs to the tumor ecosystem. Besides, VEGF is also a key modulator of EPC recruitment and preclinical studies have shown that VEGF blockade negatively modulates EPC-driven vasculogenesis (127).

Given that interactions between cells composing the tumor ecosystem and their surrounding ECM are crucial for angiogenesis
regulation, modifying the structural and biochemical properties of the stroma should also impair vessel growth (128) (Figure 3). Among all the molecules that compose the ECM, MMPs are critically relevant for angiogenesis and tumor invasion, as demonstrated by genetic ablation studies where their absence impeded angiogenic tumor growth (129). In this context, tissue inhibitors of MMPs, together with synthetic inhibitors of serine proteases, such as urokinase type plasminogen activator, are regarded as potential antiangiogenics (130). Importantly, there are many endogenous angiogenesis inhibitors composing the ECM that are inactivated during the angiogenic switch. Many laboratories are trying to reproduce these natural angiogenesis inhibitors that act through binding αvβ3 and β1 integrins in endothelial cells. Some examples include arrestin, canstatin, and tumstatin (131).

Since the combination of immune checkpoint inhibitors with VEGF targeted agents shows a strong preclinical rationale, several ongoing studies are exploring its potential clinical exploitability [as reviewed in Ref. (132)]. As an example, a study combining bevacizumab with anti-CTLA4 in melanoma patients showed an increased infiltration of immune cells and extensive morphological changes of CD31+ endothelial cells (133). In a recent study, the use of axitinib, a multireceptor inhibitor that targets VEGFR, PDGF, and c-kit, demonstrated a depletion of mast cells together with an improved T-cell response, pivotal for the therapeutic efficacy (134).

Vessel Normalization
In comparison with physiologic tissue vasculature, tumor vasculature is characterized by aberrant, dilated, disorganized, and tortuous blood vessels. Lack of pericyte association and vascular immaturity produce excessive permeability, increased hypoxia, and poor perfusion, resulting in decreased antitumor treatment efficacy. For instance, chemotherapeutic drugs and immunotherapies are not able to reach all regions of the tumor (135, 136). To overcome this challenge, combination of antitumor treatments and low doses of vascular targeting agents are used. Careful dosage of antiangiogenics are able to restore normal levels of angiogenic signals in different types of tumors, provoking decreased permeability by recruiting pericytes and tightening cell–cell junctions (137). This phenomenon is known as “vascular normalization.”

Benefits of vascular normalization have been observed in different types of tumors. The combination of bevacizumab, together with chemotherapy, produced a positive outcome in a subset of breast cancer patients (138). Furthermore, combined inhibition of VEGFR and angiopoietin-2 improves survival of mouse glioblastoma tumor models, by increasing vessel normalization and reprogramming TAMs (139). Another example of the benefits of vessel normalization include the use of trebananib, a fusion protein that inhibits angiogenesis by blocking binding of angiopoietin-1 and -2 to Tie 2 receptor. In a recent study, combination of trebananib and chemotherapy demonstrated benefits in progression-free survival in epithelial ovarian cancer patients (140).

CONCLUSION
Far ahead from the traditional idea that neoplasms are merely characterized by the tumor cells, tumors are now regarded as a heterogeneous association of both tumor and stromal cells that contribute in an interconnected fashion to malignant progression. The tumor ecosystem remains a bustling interchange of tumor cells, secreted molecules, and native tissue elements that, acting together, control the balance toward a proangiogenic program activation. In this way, the correct interaction between the components of the tumor ecosystem is critical for the success of the malignant lesion. Tumor stroma acts as a co-director for the development of vascularized growing mass, becoming the rationale driving the development of new antitumor therapies with antiangiogenic drugs.

Several years after the establishment of tumor angiogenesis as a cancer hallmark, the clinical exploitation of antiangiogenic therapies has reached a certain level of maturity (6). From the archetypal sprouting angiogenesis to describing less known mechanisms such as VM, the understanding of angiogenic mechanisms has become imperative for successful therapeutic targeting. The focus on the importance of these processes and the achievements in the clinical setting are reflected in the increasing number of drugs available to target angiogenesis mediators.

Undoubtedly, the normalization of the tumor ecosystem is an important new aspect for cancer treatment. Even though the tumor microenvironment holds many different cell types and components, the severity of the disease can be reduced by using a single effective drug, as demonstrated with antiangiogenics. Based on this observation, the combination of different therapies targeting different stromal components, together with traditional antitumor agents, could hold the key to impair cancer progression. Despite the rapid progress achieved in tumor ecosystem targeting, only a modest clinical success has been so far observed (141). Ongoing studies in the field which focus on studying the tumor ecosystem from an integrative point of view bear the potential to significantly control tumor angiogenesis and broaden the spectrum of current anticancer treatments.

AUTHOR CONTRIBUTIONS
Both IZ-G and OC have written, revised, and compiled this review.

FUNDING
The authors’ work is supported by research grants from EU- FP7-ERC (STROMALIGN ERC-StG-281830), MinEco Spain (SAF2016-79347-R), ISCIII Spain (AES, DTS17/00194), and AGAUR-Generalitat de Catalunya (2017SGR771). Some of these include European Development Regional Funds (ERDF “a way to achieve Europe”).
REFERENCES

1. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer (2001) 1:46–54. doi:10.1038/35094059

2. Radisky D, Hagonics B, Bissell MJ. Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol (2001) 11:87–95. doi:10.1016/s0959-4370(00)00360-6

3. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs (1995) 6:3–18. doi:10.1097/00001813-199502000-00001

4. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature (2001) 411:375–9. doi:10.1038/35077241

5. Shoji A, Ferra R, Usui T. Role of the microenvironment in tumor growth and in refractoriness to anti-angiogenic therapies. Drug Resist Updat (2008) 11:219–30. doi:10.1016/j.drup.2008.09.001

6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646–74. doi:10.1016/j.cell.2011.02.013

7. Polvak K, Hlavík I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet (2009) 25:30–8. doi:10.1016/j.tig.2008.10.012

8. Polvak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 9:265–73. doi:10.1038/nrc2620

9. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 19:1423–37. doi:10.1038/nm.3394

10. Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol (2014) 41:235–51. doi:10.1053/j.seminoncol.2014.02.007

11. ElShamy WM, Sinha A, Said N. Aggressiveness niche: can it be the foster ground for cancer metastasis precursors? Stem Cells Int (2016) 2016:1–7. doi:10.1155/2016/4829106

12. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) (2015) 3:83. doi:10.2147/HYP.S93413

13. Yang Y, Sun M, Wang L, Jiao B. HIFs, angiogenesis, and cancer. J Cell Biochem (2013) 114:967–74. doi:10.1002/jcb.24438

14. Vandekeere S, Dewerchin M, Carmeliet P. Angiogenesis revisited: an overview of current research. Eur J Cell Biol (2013) 92:235–51. doi:10.1016/j.ejcb.2012.12.003

15. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, et al. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest (2006) 116:3277–91. doi:10.1172/JCI29314

16. Bautch VL. Endothelial cells form a phalanx to block tumor metastasis. Nat Rev Cancer (2001) 1:1011–7. doi:10.1038/35077241

17. Risau W. Mechanisms of angiogenesis. Nature (1997) 386:671–4. doi:10.1038/386671a0

18. Raffi DC, Paila B, Butler J, Jin DK, Lyden D. Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells. Arterioscler Thromb Vasc Biol (2008) 28:217–22. doi:10.1161/ATVRAHA.107.151159

19. Brown JM. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br J Radiol (2014) 87:20130686. doi:10.1259/bjr.20130686

20. Ben Ezra R, Ralfi S, Lyden D. The Id proteins and angiogenesis. Oncogene (2001) 20:8334–41. doi:10.1038/sj.onc.1210546

21. Heissig B, Halltorf K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9-mediated release of kit-ligand. Cell (2002) 109:625–37. doi:10.1016/S0092-8674(02)00754-7

22. Deb A, Skelding KA, Wang S, Reeder M, Simper D, Caplice NM. Integrin profile and in vivo homing of human smooth muscle progenitor cells. Circulation (2004) 109:4267–73. doi:10.1161/01.CIR.0000139842.15651.B2

23. Urbich C, Dimmeler S. Endothelial progenitor cells. Trends Cardiovasc Med (2004) 14:318–22. doi:10.1016/j.tcm.2004.10.001

24. Jin F, Brockmeier U, Otterbach F, Metzen E. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell invasation. Mol Cancer Res (2012) 10:1021–31. doi:10.1158/1541-7786.MCR.11-0498

25. Kopp H-G, Hooper AT, Brockman MJ, Aveccia ST, Petit I, Luo M, et al. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest (2006) 116:3277–91. doi:10.1172/JCI29314

26. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe’er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1995) 145:759–95. doi:10.1016/S0002-9440(10)65173-5

27. Frenkel S, Barzel I, Levy J, Lin AY, Bartsch D-U, Majumdar D, et al. Angiogenesis: vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Anatom Rec (2006) 289:1456–69. doi:10.1002/ar.20657

28. Hendrix MJ, Seftor EA, Hess AR, Seftor R. Angiogenesis: vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer (2003) 3:411–21. doi:10.1038/nrc1092

29. Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopopov A, et al. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res (2005) 65:10164–9. doi:10.1158/0008-5472.CAN-05-2497

30. Sun B, Zhang S, Zhang D, Du J, Gao H, Zhao X, et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep (2006) 16:693–8. doi:10.3892/or.6.6.6938

31. Caduff JH, Fischer LC, Burri PH. Scanning electron microscope study of the developing microvasculature in the postnatal rat lung. Anat Rec (1986) 216:154–64. doi:10.1002/ar.198602160207

32. Burri PH, Plischuk R, Djovon V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn (2004) 231:474–88. doi:10.1002/dvdy.20184

33. Djovon V, Makanya AN. New insights into intussusceptive angiogenesis. EJS (2003) 9:145–58. doi:10.1007/s11403-003-0211-3

34. Dome F, Taziaux P, Boniver J, Fridman V, Delbecque K. [Ileum intussusceptum in an adult: a case report]. Rev Med Liege (2007) 62:498–500.
50. Ribatti D, Nico B, Floris C, Mangieri D, Piras F, Ennas MG, et al. Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter, and intussusceptive microvascular growth in primary melanoma. *Oncol Rep* (2005) 14:81–4. doi:10.3892/or.14.1.81

51. Watnick RS. The role of the tumor microenvironment in regulating angiogenesis. *Cold Spring Harbor Perspect Med* (2012) 2:a006676. doi:10.1101/cshperspect.a006676

52. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Hildenbrand R, Dilger I, Hörlin A, Stutte HJ. Urokinase and macrophages in ovarian cancer. *Cancer Res* (2007) 67:9180–9. doi:10.1158/0008-5472.CAN-07-0684

53. Granot D, Addadi Y, Kalchenko V, Harmelin A, Kunz-Schughart LA, Neeman M. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. *Cancer Res* (2007) 67:9180–9. doi:10.1158/0008-5472.CAN-07-0684

54. Fukumura D, Xavier R, Sugiuara T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. *Cell* (1998) 94:715–25. doi:10.1016/S0092-8674(00)01873-6

55. Theissens VLJL, Brandwijk RJMGE, Dings RPM, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. *Exp Cell Res* (2004) 299:286–93. doi:10.1016/j.yexcr.2004.06.014

56. Gilad AA, Israely T, Dafni H, Meir G, Cohen B, Neeman M. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: the role of stromal cells in tumor angiogenesis. *Int J Cancer* (2005) 117:202–11. doi:10.1002/ijc.21179

57. Albini A, Bruno A, Noonan DM, Mortara L. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. *Front Immunol* (2018) 9:527. doi:10.3389/fimmu.2018.00527

58. Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. *Immunotherapy* (2017) 9:289–302. doi:10.2217/iom.16-0135

59. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. *J Oncol* (2010) 1:10. doi:10.1155/2010/201026

60. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. *Clin Invest* (2004) 114:623–33. doi:10.1172/JCI200422087

61. Hildenbrand R, Dilger I, Hörlin A, Stutte HJ. Urokinase and macrophages in tumor angiogenesis. *Br J Cancer* (1995) 72:818–23. doi:10.1038/bjc.1995.495

62. Sanderkötter C, Steinbrink K, Goebeler M, Bharadwaj R, Sorg C. Macrophages and angiogenesis. *J Leukoc Biol* (1994) 55:410–22. doi:10.1002/1524-7000(199411)55:5<410::AID-JLB9>3.0.CO;2-2

63. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. *J Mammary Gland Biol Neoplasia* (2002) 7:177–89. doi:10.1023/A:1020304003704

64. Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, et al. Macrophage-derived growth factors B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. *Cancer Res* (2004) 64:2725–33. doi:10.1158/0008-5472.CAN-03-1489

65. Robinson SP, Ludwig C, Paulsson J, Ostman A. The effects of tumor-derived platelet-derived growth factor in vascular morphology and function in vivo revealed by susceptibility MRI. *Int J Cancer* (2007) 122:1548–56. doi:10.1002/ijc.23279

66. McCarty ME, Somcic RJ, Stoeckzig O, Wey J, Fan F, Liu W, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. *J Clin Invest* (2007) 117:2114–22. doi:10.1172/JCI31334

67. Xian X, Häkansson J, Stålberg A, Lindblom P, Betsholtz C, Gerhardt H, et al. Pericytes limit tumor cell metastasis. *J Clin Invest* (2006) 116:64–51. doi:10.1172/JCI25705

68. Hirsch E, Brancaccio M, Altruda F. Tissue-specific KO of ECM proteins. *Methods Mol Biol* (2000) 139:47–78. doi:10.1385/1-59259-063-2:47

69. Kalluri R. Angiogenesis: basement membranes: structure, assembly and role in tumour angiogenesis. *Nat Rev Cancer* (2003) 3:422–33. doi:10.1038/nrc1094

70. Chen CS, Tan J, Ten J. Mechanotransduction at cell-matrix and cell-cell contacts. *Annu Rev Biomed Eng* (2004) 6:275–302. doi:10.1146/annurev.bioeng.6.040803.140040

71. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. *Curr Opin Cell Biol* (2004) 16:558–64. doi:10.1016/j.cob.2004.07.010

72. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. *J Natl Cancer Inst* (1997) 89:1260–70. doi:10.1093/jnci/89.9.1260

73. Wong FL, Mohapatra SS, Brandvold KA, Ruddell A, Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation. *Oncogene* (2005) 24:889–901. doi:10.1038/sj.onc.1208251
92. Fernandez NT, Koch M, Rothrock C, Gollogly DK, D’Amore PA, Ryem S, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. *Clin Cancer Res* (2008) 14:1529–39. doi:10.1158/1078-0432.CCR-07-4126

93. Volpert OV, Alami RM. Wiring the angiogenic switch: Ras, Myc, and thrombospondin-1. *Cancer Cell* (2003) 3:199–200. doi:10.1016/S1535-6108(03)00056-4

94. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. *J Gen Physiol* (1929) 7:519–30. doi:10.1085/jgp.8.6.519

95. Payen VL, Porporato PE, Baselet B, Sonveaux P. Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. *Cell Mol Life Sci* (2016) 73:1333–48. doi:10.1007/s00018-015-2098-5

96. Peppelini S, Bianchetti F, Calorini L. Extracellular acidity, a “reappraised” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy. *Cancer Metastasis Rev* (2014) 33:823–32. doi:10.1007/s10555-014-9506-4

97. Suzuki A, Maeda T, Baba Y, Shimamura K, Kato Y. Acidic extracellular pH promotes epithelial mesenchymal transition in Lewis lung carcinoma model. *Cell Metastasis Rev* (2014) 14:129. doi:10.1186/s12935-014-0129-1

98. Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of tumor malignancy. *Cancer Cell* (2005) 69:4–10. doi:10.1159/000088478

99. Yoon JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. Normalization of tumor vasculature: an emerging concept in cancer treatment. *J Cell Mol Med* (2013) 17:30–54. doi:10.1111/jcmm.12004

100. Yoon JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. Normalization of tumor vasculature: an emerging concept in cancer treatment. *J Cell Mol Med* (2013) 17:30–54. doi:10.1111/jcmm.12004

101. Blouw B, Song H, Tihan T, Boex J, Ferrara N, Gerber HP, et al. The hypoxic response of tumors is dependent on their microenvironment. *Cancer Cell* (2003) 4:1320–4. doi:10.1016/S1535-6108(03)00192-9

102. Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. *Nat Rev Clin Oncol* (2014) 11:476–90. doi:10.1038/nrclinonc.2014.144

103. Mirimame M, Bata SK. Hypoxia-inducing factors as master regulators of stenness properties and altered metabolism of cancer- and metastasis-initiating cells. *J Cell Mol Med* (2013) 17:30–54. doi:10.1111/jcmm.12004

104. Lu X, Kang Y. Hypoxia and hypoxia-inducing factors: master regulators of metastasis. *Clin Cancer Res* (2010) 16:5928–35. doi:10.1158/1078-0432.CCR-10-1360

105. Padua D, Zhang XH-F, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFBeta primes breast tumors for lung metastasis seeding through angioptatin-like 4. *Cell* (2008) 133:66–77. doi:10.1016/j.cell.2008.01.046

106. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. *Oncology* (2005) 69:6–13. doi:10.1159/000088478

107. Gerhardt H, Semb H, Pericytes: gatekeepers in tumour cell metastasis? *J Mol Med* (2008) 86:135–44. doi:10.1007/s00109-007-0258-2

108. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science* (2005) 307:58–62. doi:10.1126/science.1104819

109. Yang JC, Haworth L, Sherry RM, Huw P, Schwartzzenburger DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* (2006) 355:2665–77. doi:10.1056/NEJMoa0644389

110. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Artificial, non-antibody binding fusion proteins: a wide spectrum of selectivity and specificity. *Cancer Cell* (2010) 17:30–54. doi:10.1016/j.ccell.2014.10.006

111. Krause DS, Van Etten RA. Vascular normalization and therapy. *Cancer Cell* (2013) 23:514–22. doi:10.1016/j.ccell.2005.07.007

112. Ferrara N. The role of vascular endothelial growth factor in the regulation of angiogenesis. *Kidney Int* (1999) 56:794–814. doi:10.1046/j.1523-1755.1999.00610.x

113. Jain RK, Boex J, Ferrara N. Mechanisms of antiangiogenesis drugs: past, present and future. *Cancer Metastasis Rev* (2008) 29:115–24. doi:10.1007/s00235-008-9229-9

114. Folkman J, Long DM, Becker FF. Growth and metastasis of tumor in organ culture. *Cancer* (1963) 16:453–67. doi:10.1002/1097-0412(196304)16:4<453::AID-CNCR2820160407>3.0.CO;2-Y

115. Hey T, Fiedler E, Rudolph R, Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. *Trends Biotechnol* (2000) 20:375–81. doi:10.1016/S1078-9340(05)90016-9

116. Huang Y, Hoel D, Fukushima D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. *Cancer Res* (2013) 73:2943–8. doi:10.1158/0008-5472.CAN-12-4354

117. Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor progression. *Curr Opin Biomed Eng* (2014) 16:321–46. doi:10.1011/annurev-bioeng-071813-105259
137. Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis (2017) 20:409–26. doi:10.1007/s10456-017-9562-9

138. Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A (2015) 112:14325–30. doi:10.1073/pnas.1518808112

139. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A (2016) 113:4476–81. doi:10.1073/pnas.1525360113

140. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae D-S, et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol (2016) 143:27–34. doi:10.1016/j.ygyno.2016.07.112

141. De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer (2017) 17:457–74. doi:10.1038/nrc.2017.51

Conflict of Interest Statement: OC declares that has been economically compensated with his assistance to advisory boards and conferences from Novartis, Pfizer, Ipsen, and Teva. Apart from this, there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Copyright © 2018 Zuazo-Gaztelu and Casanovas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.